UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.
Search Articles
Journal of hepatology, ISSN 0168-8278, 2015, Volume 63, Issue 6, pp. 1511 - 1522
Gastroenterology and Hepatology | Daclatasvir | Simeprevir | Treatment | Resistance-associated variants | Ledipasvir | Interferon | Hepatitis C virus | Sofosbuvir | Direct-acting antivirals | Resistanceassociated variants | Gastroenterology & Hepatology | Life Sciences & Biomedicine | Science & Technology | Uridine Monophosphate - administration & dosage | Humans | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Imidazoles - administration & dosage | Carbamates - administration & dosage | Simeprevir - administration & dosage | Uracil - administration & dosage | Benzimidazoles - administration & dosage | Ribavirin - administration & dosage | Treatment Failure | Protease Inhibitors - administration & dosage | Fluorenes - administration & dosage | Drug Therapy, Combination | Hepacivirus - drug effects | Antiviral Agents - therapeutic use | Clinical Trials as Topic | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Interferons - administration & dosage | Drug Resistance, Viral - genetics | Anilides - administration & dosage | Sofosbuvir - administration & dosage | Uridine Monophosphate - analogs & derivatives | Macrocyclic Compounds - administration & dosage | Sulfonamides - administration & dosage | Uracil - analogs & derivatives | Development and progression | Protease inhibitors | Drug resistance | Hepatitis C | Proteases | Index Medicus
Journal Article
Journal of hepatology, ISSN 0168-8278, 2017, Volume 66, Issue 6, pp. 1138 - 1148
Gastroenterology and Hepatology | Antiviral agents | Ombitasvir | Ritonavir | Ledipasvir | Real-world | Genotype 1 | Paritaprevir | Sustained virologic response | Hepatitis C, Chronic | Sofosbuvir | Dasabuvir | Randomized controlled trials | Gastroenterology & Hepatology | Life Sciences & Biomedicine | Science & Technology | Uridine Monophosphate - administration & dosage | Humans | Middle Aged | Hepatitis C, Chronic - physiopathology | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Male | Carbamates - administration & dosage | Neoplasm Recurrence, Local - etiology | Liver Neoplasms - etiology | Young Adult | Uracil - administration & dosage | Benzimidazoles - administration & dosage | Ribavirin - administration & dosage | Aged, 80 and over | Adult | Female | Fluorenes - administration & dosage | Carcinoma, Hepatocellular - etiology | Retrospective Studies | Drug Therapy, Combination | Glomerular Filtration Rate | Ritonavir - administration & dosage | Antiviral Agents - therapeutic use | Genotype | Treatment Outcome | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Spain | Anilides - administration & dosage | Antiviral Agents - adverse effects | Uridine Monophosphate - analogs & derivatives | Aged | Macrocyclic Compounds - administration & dosage | Sustained Virologic Response | Sulfonamides - administration & dosage | Cohort Studies | Uracil - analogs & derivatives | Genetic aspects | Safety and security measures | Hepatitis C virus | Clinical trials | Chronic infection | Data processing | Hepatocellular carcinoma | Multivariate analysis | Patients | Clinical outcomes | Ribavirin | Genotype & phenotype | Cohort analysis | Fibrosis | Safety | Drug therapy | Hepatitis C | Antiviral drugs | Genotypes | Index Medicus
Journal Article
Clinical infectious diseases, ISSN 1058-4838, 06/2017, Volume 64, Issue 12, pp. 1711 - 1720
real-world | HCV | HIV | DAA | Infectious Diseases | Immunology | Life Sciences & Biomedicine | Microbiology | Science & Technology | Uridine Monophosphate - administration & dosage | Anilides - therapeutic use | Hepatitis C - drug therapy | Coinfection - drug therapy | Veterans | Humans | Middle Aged | Fluorenes - therapeutic use | Hepacivirus - genetics | Male | Carbamates - administration & dosage | Practice Patterns, Physicians | Benzimidazoles - administration & dosage | Ribavirin - administration & dosage | Female | Fluorenes - administration & dosage | Hepatitis C - complications | Registries | Drug Therapy, Combination | Benzimidazoles - therapeutic use | Uridine Monophosphate - therapeutic use | Hepacivirus - drug effects | Sofosbuvir - therapeutic use | Administration, Oral | Antiviral Agents - therapeutic use | HIV Infections - virology | Ribavirin - therapeutic use | Genotype | Treatment Outcome | Antiviral Agents - administration & dosage | Coinfection - virology | Macrocyclic Compounds - therapeutic use | Anilides - administration & dosage | Sofosbuvir - administration & dosage | Uridine Monophosphate - analogs & derivatives | HIV Infections - complications | Hepatitis C - virology | HIV Infections - drug therapy | Aged | Macrocyclic Compounds - administration & dosage | Sustained Virologic Response | Carbamates - therapeutic use | Cohort Studies | Antiviral agents | Care and treatment | Dosage and administration | Hepatitis C | HIV infection | Index Medicus
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2014, Volume 384, Issue 9941, pp. 403 - 413
Internal Medicine | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Simeprevir | Double-Blind Method | Drug Administration Schedule | Humans | Middle Aged | Hepacivirus - genetics | Genotype | Male | Treatment Outcome | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Polyethylene Glycols - administration & dosage | Recombinant Proteins - administration & dosage | Interferon-alpha - administration & dosage | Heterocyclic Compounds, 3-Ring - administration & dosage | Heterocyclic Compounds, 3-Ring - adverse effects | Ribavirin - administration & dosage | Sulfonamides - adverse effects | Adult | Female | Drug Therapy, Combination | Sulfonamides - administration & dosage | Patient outcomes | Interferon alpha | Drug therapy, Combination | Hepatitis C | Drug therapy | Ribavirin | Methods | Analysis | Clinical trials | Genetic aspects | Interferon | Biological response modifiers | Hepatitis C virus | Health aspects | Hepatitis | Genotype & phenotype | Infections | Index Medicus | Abridged Index Medicus
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2014, Volume 384, Issue 9941, pp. 414 - 426
Internal Medicine | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Antiviral agents | General aspects | Viral hepatitis | Infectious diseases | Pharmacology. Drug treatments | Viral diseases | Biological and medical sciences | Medical sciences | Human viral diseases | Antibiotics. Antiinfectious agents. Antiparasitic agents | Simeprevir | Double-Blind Method | Drug Administration Schedule | Humans | Middle Aged | Hepacivirus - genetics | Genotype | Male | Treatment Outcome | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Polyethylene Glycols - administration & dosage | Recombinant Proteins - administration & dosage | Interferon-alpha - administration & dosage | Heterocyclic Compounds, 3-Ring - administration & dosage | Ribavirin - administration & dosage | Adolescent | Adult | Female | Aged | Drug Therapy, Combination | Sulfonamides - administration & dosage | Patient outcomes | Interferon alpha | Drug therapy, Combination | Hepatitis C | Drug therapy | Methods | Ribavirin | Analysis | Clinical trials | Genetic aspects | Interferon | Product development | Biological response modifiers | Hepatitis C virus | Health aspects | Hepatitis | Mortality | Index Medicus | Abridged Index Medicus
Journal Article
JAMA : the journal of the American Medical Association, ISSN 0098-7484, 03/2015, Volume 313, Issue 12, pp. 1223 - 1231
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | HIV-1 | Coinfection | Hepatitis C - drug therapy | Anilides - adverse effects | Humans | Middle Aged | Hepacivirus - genetics | Male | Carbamates - administration & dosage | Ritonavir - adverse effects | Uracil - administration & dosage | Ribavirin - administration & dosage | Adult | Female | Hepatitis C - complications | Drug Therapy, Combination | Ritonavir - administration & dosage | Treatment Outcome | Macrocyclic Compounds - adverse effects | Antiviral Agents - administration & dosage | Pilot Projects | Uracil - adverse effects | Anilides - administration & dosage | Ribavirin - adverse effects | HIV Infections - complications | Sulfonamides - adverse effects | Carbamates - adverse effects | HIV Infections - drug therapy | Macrocyclic Compounds - administration & dosage | Sulfonamides - administration & dosage | Uracil - analogs & derivatives | Drugs | Clinical trials | Hepatitis | Human immunodeficiency virus--HIV | Medical treatment
Journal Article
Gastroenterology (New York, N.Y. 1943), ISSN 0016-5085, 2016, Volume 150, Issue 7, pp. 1590 - 1598
Gastroenterology and Hepatology | NS3/4A Protease Inhibitor | Renal Disease | RUBY-I | NS5A Inhibitor | Gastroenterology & Hepatology | Life Sciences & Biomedicine | Science & Technology | Prospective Studies | Hepatitis C - drug therapy | Humans | Middle Aged | Hepacivirus - genetics | Male | Carbamates - administration & dosage | Dose-Response Relationship, Drug | Uracil - administration & dosage | Ribavirin - administration & dosage | Female | Hepatitis C - complications | Drug Therapy, Combination | Ritonavir - administration & dosage | Kidney Failure, Chronic - drug therapy | Genotype | Antiviral Agents - administration & dosage | Anilides - administration & dosage | Kidney Failure, Chronic - virology | Hepatitis C - virology | Aged | Macrocyclic Compounds - administration & dosage | Sustained Virologic Response | Sulfonamides - administration & dosage | Uracil - analogs & derivatives | Antiviral agents | Care and treatment | Chronic kidney failure | Analysis | Communicable diseases | Liver | Genetic aspects | Hepatitis C virus | Health aspects | Restaurants | Protease inhibitors | Proteases | Index Medicus | Abridged Index Medicus
Journal Article
Journal of hepatology, ISSN 0168-8278, 2017, Volume 67, Issue 2, pp. 263 - 271
Gastroenterology and Hepatology | SURVEYOR | ABT-530 | Pangenotypic | D-alanine transaminase | Hepatitis C, chronic | Interferons | Direct-acting antiviral | Genotype | ABT-493 | Sustained virologic response | Liver cirrhosis | Gastroenterology & Hepatology | Life Sciences & Biomedicine | Science & Technology | Quinoxalines - adverse effects | Humans | Middle Aged | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Pyrrolidines - administration & dosage | Pyrrolidines - adverse effects | Male | Benzimidazoles - administration & dosage | Ribavirin - administration & dosage | Treatment Failure | Adult | Female | Benzimidazoles - adverse effects | Drug Therapy, Combination | Hepacivirus - drug effects | Drug Administration Schedule | Drug Resistance, Multiple, Viral - genetics | Quinoxalines - administration & dosage | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Polymorphism, Genetic | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Sulfonamides - adverse effects | Aged | Sustained Virologic Response | Sulfonamides - administration & dosage | Alanine | Clinical trials | Chronic infection | Viruses | Proteinase inhibitors | Patients | Ribavirin | Hepatitis | Genotype & phenotype | Cirrhosis | Alanine transaminase | Interferon | Hepatitis C | Antiviral drugs | Genotypes | Index Medicus
Journal Article
The Lancet infectious diseases, ISSN 1473-3099, 2015, Volume 15, Issue 6, pp. 645 - 653
Infectious Disease | Life Sciences & Biomedicine | Infectious Diseases | Science & Technology | Uridine Monophosphate - administration & dosage | Humans | Middle Aged | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Male | Drug-Related Side Effects and Adverse Reactions - pathology | Young Adult | Benzimidazoles - administration & dosage | Time Factors | Ribavirin - administration & dosage | Aged, 80 and over | Adult | Female | Fluorenes - administration & dosage | Fluorenes - adverse effects | Uridine Monophosphate - adverse effects | Benzimidazoles - adverse effects | Hepacivirus - isolation & purification | Administration, Oral | Japan | Genotype | Treatment Outcome | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Drug-Related Side Effects and Adverse Reactions - epidemiology | Asian Continental Ancestry Group | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Uridine Monophosphate - analogs & derivatives | Aged | Hepacivirus - classification | Sofosbuvir | Care and treatment | Liver | Dosage and administration | Product development | Drug therapy, Combination | Hepatitis C virus | Hepatitis C | Health aspects | Ribavirin | Hepatitis | Genotype & phenotype | Liver cancer | Heart attacks | Liver diseases | Human immunodeficiency virus--HIV | Hepatology | Response rates | Interferon | Infections | Drug dosages | Patients | Index Medicus
Journal Article